Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kura Oncology Inc (KURA) USD0.0001

Sell:$14.71 Buy:$14.73 Change: $0.17 (1.14%)
NASDAQ:0.73%
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$14.71
Buy:$14.73
Change: $0.17 (1.14%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$14.71
Buy:$14.73
Change: $0.17 (1.14%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Contact details

Address:
3033 Science Park Rd Ste 220
SAN DIEGO
92121-1166
United States
Telephone:
+1 (858) 5008800
Website:
https://www.kuraoncology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KURA
ISIN:
US50127T1097
Market cap:
$677.45 million
Shares in issue:
45.31 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Troy Wilson
    Chairman of the Board, President, Chief Executive Officer, Principal Accounting Officer
  • Marc Grasso
    Chief Financial Officer, Chief Business Officer, Secretary
  • Kathleen Ford
    Chief Operating Officer
  • Pingda Ren
    Senior Vice President - Chemistry and Pharmaceutical Sciences
  • James Basta
    Chief Compliance Officer, Corporate Secretary, Chief Legal Officer
  • Antonio Gualberto
    Head of Development and Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.